BioMedNewsBreaks

WednesdayOct 19, 2022 9:30 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured on Stock Day Podcast

MetAlert (OTC: MLRT), a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, was featured on a recent episode of the Stock Day Podcast. MetAlert’s CEO Patrick Bertagna joined Stock Day host Everett Jolly to discuss the company’s background, current projects and focus. “We have expanded the capabilities of our SmartSole(R) platform. We have added Bluetooth, WI-FI and sensors inside of the hardware platform, which will allow us to monitor not just where someone is but also how they are doing... We are also going to be adding products that monitor how people are doing at home... On…

Continue Reading

TuesdayOct 18, 2022 1:01 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential…

Continue Reading

MondayOct 17, 2022 2:35 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone…

Continue Reading

MondayOct 17, 2022 1:36 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

Continue Reading

MondayOct 17, 2022 1:06 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

Continue Reading

MondayOct 17, 2022 12:54 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI

Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. This change often results in myriad consequences ranging from emotional and somatic changes to cognitive impairment and physical symptoms… In most cases, concussion symptoms resolve within a few days or weeks as the damaged pathways rebuild and strengthen through repetition, use and cleanup of cell debris. However, there has been growing concern that mTBI may be associated…

Continue Reading

FridayOct 14, 2022 12:06 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful,…

Continue Reading

ThursdayOct 13, 2022 11:34 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Participate at Upcoming LD Micro Main Event XV Conference

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, is slated to present at this month’s LD Micro Main Event XV Conference. Scheduled for Oct. 25–27, 2022, the three-day event will be held in Los Angeles. HeartBeam CEO and founder Branislav Vajdic, PhD, will present live during the conference. His presentation will begin at 7:30 p.m. ET on Oct. 25 and can be viewed in person or online. A replay of the presentation will also be available following the event on the HeartBeam investor relations website.…

Continue Reading

WednesdayOct 12, 2022 12:18 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination,” describes a model developed with Dr. Lisette de Pillis, a professor of life sciences and mathematics at Harvey Mudd College. NAb inhibit viral binding to the human cell receptor thereby reducing…

Continue Reading

TuesdayOct 11, 2022 1:20 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Seasoned Veteran as New Chief Medical Officer

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has named a new chief medical officer. Renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will be joining the HeartBeam executive team and will support the planned advancement of the company’s product pipeline. Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School, Fitzgerald is an interventional cardiologist and has led or participated in more than 175 clinical trials and has published some 650 manuscripts/chapters. He has…

Continue Reading